The current landscape of neoadjuvant therapy for resectable colon cancer.

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-10 DOI:10.1080/14737140.2025.2517881

Mei Chan, Tharani Krishnan, Amanda Townsend, Christos Karapetis, Amitesh Roy, Tiffany Foo, Niall Tebbutt, Tony Dhillon, Timothy Price

{"title":"The current landscape of neoadjuvant therapy for resectable colon cancer.","authors":"Mei Chan, Tharani Krishnan, Amanda Townsend, Christos Karapetis, Amitesh Roy, Tiffany Foo, Niall Tebbutt, Tony Dhillon, Timothy Price","doi":"10.1080/14737140.2025.2517881","DOIUrl":null,"url":null,"abstract":"Introduction: Neoadjuvant therapy has been proposed as a safe and effective treatment option for resectable colon cancer, providing several advantages over the current standard adjuvant protocol.Areas covered: This review summarizes the recent developments in neoadjuvant strategies for resectable colon cancer, highlighting key clinical trial data, current and emerging challenges, and the role of precision medicine in guiding treatment. Sources for this review were obtained through searches of PubMed, ClinicalTrials.gov, and relevant conference abstracts.Expert opinion: Neoadjuvant therapy is emerging as a promising approach for treating colon cancer, especially for dMMR/MSI-H colon cancer where neoadjuvant immunotherapy have shown exceptional complete pathologic response rates and durable responses. Ongoing trials are focused on identifying optimal treatment approaches that balance oncological efficacy with the minimization of toxicity. A reliable multimodal evaluation framework incorporating advanced staging techniques and biomarkers such as circulating tumor DNA is essential to guide treatment and improve patient selection.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"901-913"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2517881","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Neoadjuvant therapy has been proposed as a safe and effective treatment option for resectable colon cancer, providing several advantages over the current standard adjuvant protocol.

Areas covered: This review summarizes the recent developments in neoadjuvant strategies for resectable colon cancer, highlighting key clinical trial data, current and emerging challenges, and the role of precision medicine in guiding treatment. Sources for this review were obtained through searches of PubMed, ClinicalTrials.gov, and relevant conference abstracts.

Expert opinion: Neoadjuvant therapy is emerging as a promising approach for treating colon cancer, especially for dMMR/MSI-H colon cancer where neoadjuvant immunotherapy have shown exceptional complete pathologic response rates and durable responses. Ongoing trials are focused on identifying optimal treatment approaches that balance oncological efficacy with the minimization of toxicity. A reliable multimodal evaluation framework incorporating advanced staging techniques and biomarkers such as circulating tumor DNA is essential to guide treatment and improve patient selection.

查看原文本刊更多论文

可切除结肠癌新辅助治疗的现状。

新辅助治疗已被认为是可切除结肠癌的一种安全有效的治疗选择，与目前的标准辅助治疗方案相比，新辅助治疗有几个优点。涵盖领域：本综述总结了可切除结肠癌新辅助治疗策略的最新进展，重点介绍了关键的临床试验数据、当前和新出现的挑战，以及精准医学在指导治疗中的作用。本综述的来源是通过检索PubMed、ClinicalTrials.gov和相关会议摘要获得的。专家意见：新辅助治疗正在成为治疗结肠癌的一种有前景的方法，特别是对于dMMR/MSI-H结肠癌，新辅助免疫治疗已经显示出异常的完全病理反应率和持久的反应。正在进行的试验的重点是确定最佳的治疗方法，以平衡肿瘤疗效和毒性最小化。一个可靠的多模式评估框架，结合先进的分期技术和生物标志物，如循环肿瘤DNA，对指导治疗和改善患者选择至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.